C-o- Group In R Patents (Class 514/622)
-
Publication number: 20110106241Abstract: Amidine analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumor cells.Type: ApplicationFiled: October 2, 2010Publication date: May 5, 2011Inventors: Kevin R. Lynch, Timothy L. Macdonald, Yugesh Kharel, Thomas P. Mathews, Brian R. Wamhoff
-
Publication number: 20110092591Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: February 6, 2009Publication date: April 21, 2011Applicant: NOSCIRA S.A.Inventors: Javier Lopez Ogalla, Pilar Munoz Ruiz, Diana Alonso Gordillo, Miguel Medina Padilla, Esther Garcia Palomero, Ana Martinez Gil, Ana Castro Morera
-
Publication number: 20110091405Abstract: Compositions, kits and methods are provided for conditioning, revitalizing, volumizing or increasing the natural pigmentation of the hair, including hair on the scalp, eyelashes, eyebrows, mustache and beard, promoting healthy growth, and treating and preventing loss, thinning or miniaturization of hair due to aging, various genetic, pathological, radiation, chemotherapy, chemical treatment, environmental or other reasons.Type: ApplicationFiled: October 27, 2010Publication date: April 21, 2011Applicant: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Publication number: 20110082176Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.Type: ApplicationFiled: October 15, 2010Publication date: April 7, 2011Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
-
Publication number: 20110082212Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.Type: ApplicationFiled: September 13, 2010Publication date: April 7, 2011Inventors: James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Karen A. Veverka, Dong Jin Hwang, Jiyun Chen
-
Patent number: 7914769Abstract: Methods and compositions for treating human papillomavirus infections are described.Type: GrantFiled: April 7, 2005Date of Patent: March 29, 2011Assignees: University of Massachusetts, Tufts UniversityInventors: Elliot J. Androphy, James D. Baleja
-
Publication number: 20110071164Abstract: This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.Type: ApplicationFiled: November 9, 2010Publication date: March 24, 2011Inventors: Søren Peter OLESEN, Morten Grunnet, Palle Christophersen, Dorte STRØBÆK, Joachim Demnitz, Rie S. Hansen
-
Publication number: 20110065657Abstract: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by ?-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.Type: ApplicationFiled: September 21, 2010Publication date: March 17, 2011Inventors: Gerardo M Castillo, Paula Choi, Alan D Snow
-
Publication number: 20110064805Abstract: A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm3/g, containing I-type crystals and having an average particle size of over 30 to 250 ?m, a specific surface area of 0.1 to less than 20 m2/g, a repose angle of 25° to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in water.Type: ApplicationFiled: November 9, 2010Publication date: March 17, 2011Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Kazuhiro Obae, Hideki Amakawa, Ichiro Ibuki
-
Publication number: 20110053904Abstract: The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.Type: ApplicationFiled: August 19, 2010Publication date: March 3, 2011Inventors: Sabine Kolczewski, Emmanuel Pinard
-
Patent number: 7897162Abstract: Disclosed herein is a pharmacophore model for arthropod repellent activity and methods of making and using thereof. The pharmacophore comprises two hydrophobic aliphatic functions, one aromatic function and one hydrogen bond acceptor function. The pharmacophore model was made using a test set of arthropod repellent compounds. Also disclosed are arthropod repellent compounds identified by screening databases with the pharmacophore model. Also disclosed are methods of repelling arthropods from a surface or area. Compositions and formulations comprising the compounds of the present invention as well as objects having the compounds of the present invention are disclosed.Type: GrantFiled: December 24, 2008Date of Patent: March 1, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Raj K. Gupta, Apurba K. Bhattacharjee, Donna Ma Lee
-
Publication number: 20110046128Abstract: A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.Type: ApplicationFiled: September 13, 2010Publication date: February 24, 2011Applicant: AURIMMED PHARMA, INC.Inventors: Amir Pesyan, Manuel F. Balandrin
-
Publication number: 20110039853Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 19, 2008Publication date: February 17, 2011Inventor: Soren Ebdrup
-
Publication number: 20110028562Abstract: The subject of the invention is a group of new derivatives of aminoalka?ols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl)aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production of a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as in relieving neuropathic or inflammatory pain.Type: ApplicationFiled: January 19, 2009Publication date: February 3, 2011Inventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
-
Publication number: 20110015265Abstract: The present invention provides a method for controlling diseases on turfgrass which comprises applying to turfgrass that has been cut back an effective amount of a compound of formula (1).Type: ApplicationFiled: July 13, 2010Publication date: January 20, 2011Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Masanao TAKAISHI
-
Publication number: 20110015272Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.Type: ApplicationFiled: January 12, 2010Publication date: January 20, 2011Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
-
Publication number: 20110009447Abstract: Substituted benzoic acid amides of formula (I) and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of benzoic acid amides are described.Type: ApplicationFiled: April 24, 2001Publication date: January 13, 2011Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch
-
Patent number: 7867511Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: GrantFiled: January 23, 2004Date of Patent: January 11, 2011Assignee: Travanti Pharma Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Publication number: 20100331187Abstract: The present invention relates to physically stable oil dispersions. It also relates to a method for activating bentones that are designed for use with a low polarity organic systems. It also relates to physically stable oil dispersions comprising said activated bentone.Type: ApplicationFiled: June 9, 2008Publication date: December 30, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Kirsty Jane Williams, Johathan Mark Richards
-
Publication number: 20100331366Abstract: Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 19, 2008Publication date: December 30, 2010Applicant: High Point Pharmaceuticals ,LLCInventor: Soren Ebdrup
-
Publication number: 20100331383Abstract: The present invention provides methods for treating Acquired Immunodeficiency Syndrome (AIDS) and other viral diseases and Human Immunodeficiency Virus (HIV) related infections by administering one or more compounds of formula I: wherein: the dotted line represents a single or a double bond; and R1 and R2 are the same or different and independently of each other represent —CH2OH, —CH2OR4, —CH(OH)CH3, —CH(OR4)CH3 or a group represented by the formula: or salts or hydrates thereof in a carrier which minimizes micellar formation or van der Waals attraction of molecules of said compound. The invention also provides S enantiomeric forms of such compounds which possess the ability to inhibit cell growth whilst being of low toxicity to such cells and methods of making such compounds.Type: ApplicationFiled: July 12, 2010Publication date: December 30, 2010Applicant: Novaremed LimitedInventor: Eliahu Kaplan
-
Publication number: 20100317732Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.Type: ApplicationFiled: December 29, 2008Publication date: December 16, 2010Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: Curtis J. Henrich, Heidi R. Bokesch, Laura K. Cartner, Richard W. Fuller, Kirk R. Gustafson, Kentaro Takada, James B. McMahon, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean
-
Publication number: 20100311830Abstract: A method of producing in a composition adapted to be applied to the mucous membranes, the physiological effects of menthol at a reduced menthol concentration, by the partial replacement of menthol by a cooling and flavour blend, including (a) at least one compound selected from the group consisting of lactoyl ethanolamide, nonanoic acid vanillyl amide and menthyl lactate; and (b) at least one compound of the Formula I in which the dotted line represents an optional single bond, the moieties R1, R2, R3, R4 and R5 being independently selected from H, CH3 and OH, three moieties being H, one CH3 and one OH, such that (i) when the optional single bond is absent, one of R1 and R5 is OH only when R3 is H; and (ii) when the optional single bond is present, R3 is CH3 and one of R1 and R5 is OH.Type: ApplicationFiled: May 20, 2010Publication date: December 9, 2010Applicant: Givaudan S.A.Inventors: Marco DE JONGE, Cornelis Winkel, Sarah Barrie Machover, Stefan Michael Furrer, Alexander P. Tondeur
-
Publication number: 20100311593Abstract: The invention relates to novel compounds of the formula (I), in which W, X, Y, Z and CKE are each as defined above, to several methods and intermediates for preparation thereof and to the use thereof as pesticides and/or herbicides. The invention also relates to selective herbicidal compositions which comprise firstly haloalkylmethyleneoxyphenyl-substituted ketoenols and secondly a compound which improves crop plant compatibility. The present invention further relates to the enhancement of the action of crop protection compositions comprising especially haloalkylmethyleneoxyphenyl-substituted ketoenols, by the addition of ammonium or phosphonium salts and optionally penetration enhancers, to the corresponding compositions, to methods for production thereof and to the use thereof in crop protection as insecticides and/or acaricides and/or for preventing undesired plant growth.Type: ApplicationFiled: March 11, 2010Publication date: December 9, 2010Applicant: Bayer Cropscience AGInventors: Reiner Fischer, Thomas Bretschneider, Stefan Lehr, Eva-Maria Franken, Olga Malsam, Arnd Voerste, Ulrich Görgens, Jan Dittgen, Dieter Feucht, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Alfred Angermann
-
Publication number: 20100298308Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: ApplicationFiled: November 14, 2006Publication date: November 25, 2010Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
-
Publication number: 20100298356Abstract: Compounds of the general formula (I), wherein the substituents are as defined in claim 1, are useful as fungicides.Type: ApplicationFiled: September 3, 2008Publication date: November 25, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Fiona Kessabi Murphy, Hans-Georg Brunner, Renaud Beaudegnies, Laura Quaranta, Frederik Cederbaum, Jayant Umarye
-
Publication number: 20100286197Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.Type: ApplicationFiled: July 20, 2010Publication date: November 11, 2010Inventors: Adnan M.M. Mjalli, Rober C. Andrews, Ramosh Gopalaswamy, Chris Wysong
-
Publication number: 20100286125Abstract: Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.Type: ApplicationFiled: March 28, 2008Publication date: November 11, 2010Inventors: Alan T. Johnson, Seongjin Kim
-
Publication number: 20100280113Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: July 14, 2010Publication date: November 4, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Publication number: 20100279327Abstract: The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention also relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP.Type: ApplicationFiled: March 26, 2010Publication date: November 4, 2010Applicant: BiPar Sciences, Inc.Inventors: Valeria S. OSSOVSKAYA, Barry M. SHERMAN
-
Publication number: 20100267827Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: October 21, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
-
Publication number: 20100267773Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: ApplicationFiled: February 23, 2010Publication date: October 21, 2010Inventors: James T. DALTON, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20100266714Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: ApplicationFiled: October 29, 2008Publication date: October 21, 2010Inventors: Christopher S Burgey, Diem Nguyen, Zhengwu Deng, Daniel V. Paone, Craig M. Potteiger, Joseph P. Vacca
-
Publication number: 20100261772Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.Type: ApplicationFiled: May 24, 2010Publication date: October 14, 2010Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
-
Publication number: 20100247606Abstract: Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between 10 days and 1 year.Type: ApplicationFiled: March 25, 2009Publication date: September 30, 2010Applicant: ALLERGAN, INC.Inventors: Michael R. ROBINSON, James A. Burke, Hui Liu, Werhner C. Orilla, Lon T. Spada, Scott Whitcup, Alazar N. Ghebremskel, Patrick M. Hughes, Kun Xu, Marianne M. Do
-
Publication number: 20100249228Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.Type: ApplicationFiled: March 23, 2010Publication date: September 30, 2010Inventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
-
Publication number: 20100249123Abstract: The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1n are defined as in formula I; invention compounds are modulators of follicle-stimulating hormone—(“FSH”) which are useful for male and female contraception as well as other disorders modulated by FSH receptor.Type: ApplicationFiled: March 19, 2008Publication date: September 30, 2010Applicant: ADDEX PHARMA SAInventors: Beatrice Bonnet, Brice Campo, Luca Raveglia, Mauro Riccaboni
-
Publication number: 20100249075Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.Type: ApplicationFiled: February 10, 2006Publication date: September 30, 2010Applicant: ELI LILLY AND COMPANYInventors: Venkatesh Krishnan, Julian Stanley Kroin, Bryan Hurst Norman, Elizabeth Marie Thomas
-
Publication number: 20100240677Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.Type: ApplicationFiled: January 26, 2010Publication date: September 23, 2010Applicant: AVENTIS PHARMA LIMITEDInventors: Garry FENTON, Tahir Nadeem MAJID, Malcolm Norman PALFREYMAN
-
Publication number: 20100234466Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.Type: ApplicationFiled: January 6, 2010Publication date: September 16, 2010Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale
-
Publication number: 20100227844Abstract: The present invention relates to methods of treating Alzheimer's Disease and Alzheimer's Disease related disorders comprising administration of a compound of structural formula: (I), or a pharmaceutically acceptable salt thereof, as a monotherapy or in combination with an anti-Alzheimer's Disease agent. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.Type: ApplicationFiled: October 20, 2008Publication date: September 9, 2010Inventors: Tung M. Fong, Leonardus H.T. Van Der Ploeg
-
Patent number: 7790770Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.Type: GrantFiled: November 13, 2006Date of Patent: September 7, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, Heather Finlay, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
-
Publication number: 20100216746Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.Type: ApplicationFiled: June 5, 2008Publication date: August 26, 2010Applicant: GLAXOSMITHKLINE LLCInventors: PEK Yoke Chong, Andrew James Peat, Paul Richard Sebahar, Michael Youngman, Huichang Zhang
-
Publication number: 20100216877Abstract: A prostaglandin composition comprising prostaglandin and a low-density polyethylene container are disclosed. The prostaglandin compositions are stable in polyethylene containers over longer period of time.Type: ApplicationFiled: February 18, 2010Publication date: August 26, 2010Applicant: MICRO LABS LIMITEDInventors: Rajesh Kshirsagar, Chandrashekar Kadam, Sachin Jain, SM Mudda
-
Publication number: 20100210652Abstract: A method of controlling harmful fungi which are resistant to carboxamide fungicides consists in applying a fungicidally active amount of a compound of the general formula (I) where —R denotes, for example: —OCH3, —OC2H5 or —OCH2—C?CH and where —X denotes either —Cl or —F and where —Z— denotes, for example, a group: preventatively to the plants.Type: ApplicationFiled: August 24, 2007Publication date: August 19, 2010Inventors: Gerd Stammler, Barbara Nave, Ulrich Schöfl, Reinhard Stierl
-
Publication number: 20100204335Abstract: The invention provides a kit for enhancing the appearance of eyelashes, comprising an eyelash enhancing composition and delivery system. The eyelash enhancing composition comprises an effective amount of 0.03% bimatoprost. The delivery system comprises a plurality of applicator brushes designed to deliver a fraction of 1-drop bimatoprost dose to the target area.Type: ApplicationFiled: November 30, 2009Publication date: August 12, 2010Applicant: ALLERGAN, INC.Inventors: Frederick C. Beddingfield, John G. Walt, Christine Somogyi, Chetan Pujara, Julie Albright
-
Patent number: 7772425Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: May 22, 2009Date of Patent: August 10, 2010Assignee: Eli Lilly and CompanyInventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
-
Patent number: 7767854Abstract: The invention provides the following compound (I): wherein R1 is methoxy group, hydroxyl group or hydrogen atom; R2 is hydrogen atom, C1-4 alkyl group, C1-4 alkylcarbonyl group or arylcarbonyl group; D is a group of the following formula (A), (B), or (C). The compound is useful as a medicament for treating neuropathic pain or pain caused by various diseases such as rheumatoid arthritis and osteoarthritis, and inflammation.Type: GrantFiled: April 20, 2006Date of Patent: August 3, 2010Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshiya Morie, Yasunori Tsuzuki, Keiji Adachi, Kazuhiro Mizuno, Katsuyoshi Kawashima, Isao Shimizu, Daisuke Ishii
-
Publication number: 20100163032Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.Type: ApplicationFiled: December 22, 2009Publication date: July 1, 2010Inventors: Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden